$0.96 +0.02 (2.08%)

PharmaCyte Biotech, Inc. Common Stock (PMCB)

PharmaCyte Biotech, Inc. is a biotechnology company focused on developing cell therapy-based treatments for cancer and other serious diseases. The company leverages its proprietary live-cell encapsulation platform to create therapies that deliver targeted and sustained drug release, aiming to improve patient outcomes.

🚫 PharmaCyte Biotech, Inc. Common Stock does not pay dividends

Company News

Pancreatic Cancer Treatment Market Size Worth USD 10.53 Billion by 2032 Driven by Rising Prevalence of Obesity, Smoking, and Alcohol Consumption | Research by SNS Insider
GlobeNewswire Inc. • Sns Insider • August 27, 2024

The pancreatic cancer treatment market is expected to grow significantly, driven by the increasing prevalence of the disease and the development of innovative therapies. Factors like the rising geriatric population, emerging chemotherapies, and increased healthcare investments in Asia-Pacific and the Middle East are further propelling the market ...

BMYPFEAMGNMRKAZNTEVA
Meta Platforms Announces $40 Billion Share Buyback - Buyback Wednesdays
Seeking Alpha • Asif Suria • February 9, 2023

Meta Platforms, Inc. announced a whopping $40 billion share repurchase program.

AAPLARWONPINSSWKSVRTX
The Daily Biotech Pulse: Moderna's Vaccine Produces Durable Response Against Variants, FDA Approves Jazz's Sleep Disorder Drug, Dermata IPO
Benzinga • Shanthi Rexaline • August 13, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 12) Adagio Therapeutics, Inc. (NASDAQ: ADGI) (IPOed Aug. 6) Alkermes plc (NASDAQ: ALKS) Bio-Rad Laboratories, Inc. (NYSE: BIO) Candel Therapeutics, Inc. (NASDAQ: CADL) (IPOed July 26) Century Therapeutics...

PASGACADAXSMBMEATXMDIMRA